The proposal would provide $5 million in 2025-26 to review women-specific health items on the Medicare Benefits Schedule (MBS) and corresponding treatments on the Pharmaceutical Benefits Schedule (PBS). This review would identify best practice women-specific medical services which should be included, and ensure clinically effective services and treatments remain affordable and accessible to better support women’s health and wellbeing.

The proposal would be non-ongoing and start from 1 July 2025.